Skip to main content
Fig. 1 | Cancer Imaging

Fig. 1

From: Arterial enhancement fraction in evaluating the therapeutic effect and survival for hepatocellular carcinoma patients treated with DEB-TACE

Fig. 1

Flowchart showing the patient selection. HCC lesions with haemorrhage, main trunk tumor thrombosis of portal vein, or arterioportal shunt were not eligible for creating quantitative color mapping and therefore excluded. Fourteen patients who obtained complete response were excluded from post-treatment analyses because of the absence of residual tumors. DEB-TACE: drug-eluting bead transarterial chemoembolization; HCC: hepatocellular carcinoma; DSA: digital subtraction angiography

Back to article page

Cancer Imaging

ISSN: 1470-7330

Contact us